The Australian Angelman Syndrome Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delay and learning disabilities; absence or near absence of speech; inability to coordinate voluntary movements (ataxia); tremulousness with jerky movements of the arms and legs and a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling. Although those with the syndrome may be unable to speak, many gradually learn to communicate through other means such as gesturing.

In Australia, Angelman syndrome affects males and females in equal numbers. The prevalence of Angelman syndrome is estimated to be out of the whole population, people affected by Angelman syndrome are 1,659. Angelman syndrome is not a degenerative disease. Children with Angelman syndrome can expect a normal lifespan.



Market Growth Drivers

Angelman syndrome treatment market is expected to grow over the forecast period, due to increasing research activities and R&D expenditure (for instance FAST Australia has raised over two million dollars of which $1.5 million has been invested in research and education. They have held three conferences with researchers and experts from within Australia and globally). Government initiatives in developing new treatment options for Angelman syndrome are expected to drive the growth of the Australian Angelman syndrome treatment market over the forecast period 2020-2028. Furthermore, the effectiveness of the treatment by reducing the effect of the symptoms is also driving the growth of the Australian Angelman syndrome treatment market. Improvements in the healthcare sector are further facilitating the growth of the Angelman syndrome treatment market.

However, rising treatment costs and lack of awareness among patients and physicians & low diagnosis rate because of difficulty in diagnosis about Angelman Syndrome are among the major factors acting as restraints in the forecast period.